A Review of and Recommendations for the Management of Patients with Life-Threatening Dabigatran-Associated Hemorrhage

Journal of Intensive Care Medicine

Volumn 30, Issue 8, 2015, Pages 462-472

  Kumar, Rohit ^a   Smith, Roy E ^a   Henry, Brian L ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

bleeding; coagulation; dabigatran; dialysis; thrombin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DABIGATRAN; DESMOPRESSIN; FIBRINOGEN; FRESH FROZEN PLASMA; HEMOGLOBIN; VITAMIN K GROUP; ANTICOAGULANT AGENT; ANTIDOTE; ANTITHROMBIN; CHARCOAL;

AGED; ANTICOAGULATION; BLEEDING; BLOOD CELL COUNT; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS HEMODIALYSIS; CRYOPRECIPITATE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG BLOOD LEVEL; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; FEMALE; FIBRINOGEN BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LAPAROTOMY; LIVER FUNCTION TEST; MALE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; REVIEW; SUBDURAL HEMATOMA; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TOTAL QUALITY MANAGEMENT; VERY ELDERLY; CHEMICALLY INDUCED; HEMODIALYSIS; INTRACRANIAL HEMORRHAGES; MORTALITY; PARTIAL THROMBOPLASTIN TIME; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STROKE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ANTICOAGULANTS; ANTIDOTES; ANTITHROMBINS; CHARCOAL; DABIGATRAN; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITALS, UNIVERSITY; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MULTIPLE ORGAN FAILURE; PARTIAL THROMBOPLASTIN TIME; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE; TREATMENT OUTCOME;

EID: 84946135517     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066614527417     Document Type: Review

References (46)

1. Boehringer Ingelheim Pharmaceuticals, Inc. Pradaxa (Dabigatran Etexilate Mesylate) Prescribing Information. 2012. www.pradaxa.com. Accessed June 21, 2013.
2. US Food and Drug Administration. FDA Drug Safety Communication: Safety Review of Post-Market Reports of Serious Bleeding Events with the Anticoagulant Pradaxa (Dabigatran Etexilate Mesylate). 2011. www.fda.gov/Drugs/DrugSafety/ucm282724.htm#sa. Accessed June 21, 2013.
3. Stangier J, Clemens A,. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009; 15 (suppl 1): 9S-16S.
4. van Ryn J, Hauel N, Waldmann L, Wienen W,. Dabigatran inhibits both clot-bound and fluid-phase thrombin in vitro: comparison to heparin and hirudin. Arterioscler Thromb Vasc Biol. 2008; 28: e136-e137.
5. Hankey GJ, Eikelboom JW,. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011; 123 (13): 1436-1450.
6. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W,. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64 (3): 292-303.
7. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361 (12): 1139-1151.
8. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103 (6): 1116-1127.
9. Peacock WF, Gearhart MM, Mills RM,. Emergency management of bleeding associated with old and new oral anticoagulants. Clin Cardiol. 2012; 35 (12): 730-737.
10. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011; 32 (22): 2781-2789.
11. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2013; 127 (5): 634-640.
12. McCullough J,. Overview of platelet transfusion. Semin Hematol. 2010; 47 (3): 235-242.
13. Stangier J, Rathgen K, Stähle H, Mazur D,. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010; 49 (4): 259-268.
14. E.M.A. EU. Summary of Product Characteristic: PRADAXA. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000829/WC500041059.pdf. Accessed September 15, 2013.
15. Health Canada. Boehringer Ingelheim Canada Ltd. PRADAXA Product Monograph. Date of Revision: May 14, 2013. http://www.boehringer-ingelheim.ca/content/dam/internet/opu/ca-EN/documents/humanhealth/product-monograph/PradaxaPMEN0513.pdf. Accessed September 15, 2013.
16. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM,. Impact of dabigatran on a large panel of routine or specific coagulation assays: laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012; 107 (5): 985-997.
17. Brunetti L, Bandali F,. Dabigatran: is there a role for coagulation assays in guiding therapy? Ann Pharmacother. 2013; 47 (6): 828-840.
18. Singh T, Maw TT, Henry BL, et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol. 2013; 8 (9): 1533-1539.
19. van Ryn J, Baruch L, Clemens A., van Ryn J, Baruch L, Clemens A,. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med. 2012; 125 (4): 417-420.
20. Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008; 47 (1): 47-59.
21. Zehnder JL,. Clinical use of coagulation tests. http://www.uptodate.com/contents/clinical-use-of-coagulation-tests. Accessed September 15, 2013.
22. Adcock DM, Gosselin R, Kitchen S, Dwyre DM,. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol. 2013; 139 (1): 102-109.
23. Lange U, Nowak G, Bucha E,. Ecarin chromogenic assay - a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb. 2003; 33 (4): 184-191.
24. Mani H, Kasper A, Lindhoff-Last E,. Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. J Thromb Thrombolysis. 2013; 36 (2): 187-194.
25. Antovic JP, Skeppholm M, Eintrei J, et al. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol. 2013; 69 (11): 1875-1881.
26. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G,. American college of chest physicians. Oral anticoagulant therapy: antithrombotic therapy and prevention of Thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012; 141 (2 suppl): e44S-e88 S.
27. van Ryn J, Sieger P, Kink-Eiband M, et al. Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro [Abstract no. 1065]. 51st ASH Annual Meeting and Exposition. New Orleans (LA): American Society of Hematology. 2009.
28. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012; 87 (suppl 1): S141-S145.
29. Chang DN, Dager WE, Chin AI,. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013; 61 (3): 487-489.
30. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW,. Recombinant factor VIIa (rhFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood. 2012; 119: 2172-2174.
31. Khadzhynov D, Wagner F, Formella S, et al. Effective elimination of dabigatran by haemodialysis: a phase I single-centre study in patients with end-stage renal disease. Thromb Haemost. 2013; 109 (4): 596-605.
32. Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc. 2004; 79 (12): 1495-1500.
33. Ilyas C, Beyer GM, Dutton RP, et al. Recombinant factor VIIa for warfarin-associated intracranial bleeding. J Clin Anesth. 2008; 20 (4): 276-279.
34. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G,. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012; 108 (2): 217-224.
35. van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W,. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. Haematologica. 2008; 93 (s1): 148.
36. Levi M, Levy JH, Andersen HF, Truloff D,. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010; 363 (19): 1791-1800.
37. Key NS, Negrier C,. Coagulation factor concentrates: past, present, and future. Lancet. 2007; 370 (9585): 439-448.
38. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011; 42 (12): 3594-3599.
39. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M,. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124 (14): 1573-1579.
40. Weitz JI, Quinlan DJ, Eikelboom JW,. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation. 2012; 126 (20): 2428-2432.
41. Dager WE, Gosselin RC, Roberts AJ,. Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med. 2013; 41 (5): e42-e46.
42. Dentali F, Marchesi C, Pierfranceschi MG, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost. 2011; 106 (3): 429-438.
43. Friedman KD, Menitove JE,. Preparation and clinical use of plasma and plasma fractions. In: Beutler E, Lichtman MA, Coller BS, et al.eds. Williams' Hematology, 6th ed. New York, NY: McGraw-Hill; 2001: 1917.
44. Holland LL, Foster TM, Marlar RA, Brooks JP,. Fresh frozen plasma is ineffective for correcting minimally elevated international normalized ratios. Transfusion. 2005; 45 (7): 1234-1235.
45. Zeigler ZR, Megaludis A, Fraley DS,. Desmopressin (d-DAVP) effects on platelet rheology and von Willebrand factor activities in uremia. Am J Hematol. 1992; 39 (2): 90-95.
46. Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-Arginine vasopressin shortens the bleeding time in uremia. N Engl J Med. 1983; 308 (1): 8-12.